肝硬変Rx CDS システム
肝硬変患者のガイドライン順守と臨床転帰に対する新しい臨床意思決定支援システムである肝硬変Rxの効果を評価する実用的なランダム化対照試験
The aim of the study is to compare the effect of CirrhosisRx, a novel clinical decision support (CDS) system for inpatient cirrhosis care, versus "usual care" on adherence to national quality measures and clinical outcomes for hospitalized patients with cirrhosis.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
Each year, there over 200,000 hospitalizations for cirrhosis in the United States. Over one-third of these patients are readmitted within 30 days, and up to 10% will die in the hospital. Despite national quality measures and care guidelines, cirrhosis care remains suboptimal and highly variable.
Clinical Decision Support (CDS) systems present an attractive strategy to improve guideline-adherence due to low implementation costs. These systems, however, remain largely untested in cirrhosis care and it remains unknown whether they are effective at improving guideline-adherence and whether improving guideline-adherence changes clinical outcomes in cirrhosis care. The investigators have designed "CirrhosisRx," a cirrhosis-specific CDS system, to address these evidence gaps.
This study intends to compare effect of CirrhosisRx versus "usual care" on adherence to quality measures and clinical outcomes through a pragmatic randomized controlled trial (pRCT). Randomization will be based on stepped-wedge cluster randomization of treatment teams at our institution.
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- 適用できない
連絡先と場所
研究連絡先
研究連絡先
- 名前:Jin Ge, MD, MBA
- 電話番号:415-502-8070
- メール:jin.ge@ucsf.edu
研究場所
-
-
California
-
San Francisco、California、アメリカ、94143
- 募集
- University of California San Francisco Medical Center
-
コンタクト:
- Jin Ge, MD, MBA
- 電話番号:415-502-8070
- メール:jin.ge@ucsf.edu
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- All adult (age ≥ 18 years) patients who have cirrhosis identified based on 1+ chronic liver disease and 1+ cirrhosis (or its complications) International Classification of Diseases, Revision 10 diagnosis codes OR mention of cirrhosis or portal hypertension (or their complications) in clinical documentation admitted at our institution.
Exclusion Criteria:
- Children (age < 18 years)
- patients who do not meet the cirrhosis definition criteria as noted above
- ambulatory patients
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:ヘルスサービス研究
- 割り当て:ランダム化
- 介入モデル:クロスオーバー割り当て
- マスキング:なし(オープンラベル)
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:CirrhosisRx
Providers in this arm will have access to the CirrhosisRx CDS system, which aggregates and organizes clinical data, presents them in clinically relevant/intuitive fashion for cirrhosis care, and linked to order sets consistent with national guidelines. |
CirrhosisRx is a cirrhosis-specific CDS that organizes clinical data into clinically relevant groupings and links them to order sets consistent with national practice guidelines for inpatient cirrhosis care. |
|
介入なし:Usual Care
Providers in this arm will not have access to the CirrhosisRx CDS system. |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Aggregate adherence to quality measures
時間枠:During the hospitalization, approximately 7 days
|
This outcome is the aggregate adherence to five American Gastroenterological Association (AGA) and American Association for the Study of Liver Disease (AASLD) quality measures applicable to hospitalized patients with cirrhosis. The calculation for the measure will be the total number of admissions satisfying the five AGA/AASLD quality measures divided by the total number of addressable admissions (e.g. hospitalizations in which these quality metrics could be applied). In the cases which an admission could satisfying two or more metrics, this single admission will be multiple times per the number of times metrics could be potentially applied. |
During the hospitalization, approximately 7 days
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Inpatient mortality
時間枠:During the hospitalization, approximately 7 days
|
This outcome is death during the admission |
During the hospitalization, approximately 7 days
|
その他の成果指標
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Reach of CirrhosisRx
時間枠:Through study completetion, approximately 36 months
|
Number of patients and clinicians randomized to CirrhosisRx |
Through study completetion, approximately 36 months
|
|
Adoption of CirrhosisRx
時間枠:Through study completetion, approximately 36 months
|
Proportion of clinicians using CirrhosisRx in the intervention arm |
Through study completetion, approximately 36 months
|
|
Implementation of CirrhosisRx
時間枠:Through study completetion, approximately 36 months
|
Proportions of clinicians implementing an order set through CirrhosisRx |
Through study completetion, approximately 36 months
|
|
Maintenance of CirrhosisRx
時間枠:Through study completetion, approximately 36 months
|
Rate of use over time and contamination rate |
Through study completetion, approximately 36 months
|
|
Average time spent on CirrhosisRx
時間枠:Through study completetion, approximately 36 months
|
Average time spent on CirrhosisRx - defined as the total time all clinicians spent on the system divided by the number of clinicians using the system |
Through study completetion, approximately 36 months
|
協力者と研究者
捜査官
捜査官
- 主任研究者:Jin Ge, MD, MBA、University of California, San Francisco
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
その他の研究ID番号
- 23-39379
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。